CGRP1 Antibody - Humanized, IgG4SP, (Research Grade galcanezumab Biosimilar) - Low Endotoxin, Azide and BSA Free

Novus Biologicals | Catalog # NBP3-28517

Recombinant Monoclonal Antibody
Novus Biologicals

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG4 expressed in CHO

Format

Low Endotoxin, Azide and BSA Free
View all CGRP1 Primary Antibodies »

Product Specifications

Immunogen

CALCA / CGRP

Reactivity Notes

Predicted species reactivity: Rat

Clonality

Monoclonal

Host

Human

Isotype

IgG4

Description

The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.

Also known as 'galcanezumab'.

IgG4SP is human IgG4 with S228P mutation.

This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.

Endotoxin Level

< 0.001EU/ug,determined by LAL method.

Applications

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

  • Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
  • Spillover Popups - Visualize the spectra of individual fluorochromes
  • Antigen Density Selector - Match fluorochrome brightness with antigen density
Build Your Panel Now
Flow Cytometry

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Formulation

Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)

Format

Low Endotoxin, Azide and BSA Free

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C in powder form. Store at -80C once reconstituted.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: CGRP1

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide that functions as a vasodilator, has an important role in pain pathways, and has become a target for migraine treatment (1). The CGRP peptide is characterized by an N-terminal disulfide bond, an alpha-helical structure than plays a role in binding affinity, and an amine C-terminal (1,2). CGRP exists in alpha- and beta-isoforms encoded by genes CALCA (CALC I) and CALCB (CALC II), respectively (1,2). alphaCGRP and betaCGRP only differ by three amino acids, have greater than 90% homology, and each peptide has a theoretical molecular weight of ~3.8 kDa (1,2). alphaCGRP is the predominant peptide form and is expressed in regions of the central and peripheral nervous system, including sensory fibers and the trigeminal ganglia (1,2). Other members of the CGRP gene family includes adrenomedullin, and adrenomedullin 2 (intermedin), amylin, and calcitonin (1,2). When CGRP is released from nerve fibers and blood vessels, it binds a CGRP receptor complex (1-3). The receptor consists of G-protein coupled receptor calcitonin-like receptor (CLR) that is associated with an accessory protein receptor activity-modifying protein (RAMP) (2,3).

Signaling of CGRP and its receptor are involved in vasodilation, neurogenic inflammation, and peripheral sensitization of nociceptors, all of which relate to migraine pathophysiology (2-3). Studies have found that CGRP is both released during migraines and can also induce migraines (3-5). Under normal conditions CGRP levels are typical and neurotransmission is relative; however, migraine triggers including light and sound can increase CGRP levels, enhance neurotransmission, and alter the pain and sensory aversions associated with migraines (2). Given its role, CGRP and its receptor have been the target of many migraine therapeutics including small molecule agonists called gepants and monoclonal antibodies (3-5). Ubrogepant and Rimegepant, two small molecule CGRP receptor agonists, have been FDA approved while another agonist, Atogepant, is ongoing in clinical trials (3,5). Additionally, four monoclonal antibodies against either CGRP or its receptor that are used to block signaling have been FDA approved: Eptinezumab, Fremanezumab, Galcanezumab, and Erenumab (3-5).

References

1. Russell, F. A., King, R., Smillie, S. J., Kodji, X., & Brain, S. D. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. Physiological reviews, 94(4), 1099-1142. https://doi.org/10.1152/physrev.00034.2013

2. Russo A. F. (2015). Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual review of pharmacology and toxicology, 55, 533-552. https://doi.org/10.1146/annurev-pharmtox-010814-124701

3. Wattiez, A. S., Sowers, L. P., & Russo, A. F. (2020). Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert opinion on therapeutic targets, 24(2), 91-100. https://doi.org/10.1080/14728222.2020.1724285

4. Deen, M., Correnti, E., Kamm, K., Kelderman, T., Papetti, L., Rubio-Beltran, E., Vigneri, S., Edvinsson, L., Maassen Van Den Brink, A., & European Headache Federation School of Advanced Studies (EHF-SAS) (2017). Blocking CGRP in migraine patients - a review of pros and cons. The journal of headache and pain, 18(1), 96. https://doi.org/10.1186/s10194-017-0807-1

5. de Vries, T., Villal0n, C. M., & MaassenVanDenBrink, A. (2020). Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacology & therapeutics, 211, 107528. https://doi.org/10.1016/j.pharmthera.2020.107528

Long Name

Calcitonin Gene Related Peptide I

Alternate Names

a-CGRP, alpha-CGRP, CGRP 1, CGRP alpha, CGRP I

Gene Symbol

CALCA

UniProt

P06881 (Human)

Additional CGRP1 Products

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customer Reviews

There are currently no reviews for this product. Be the first to review CGRP1 Antibody - Humanized, IgG4SP, (Research Grade galcanezumab Biosimilar) - Low Endotoxin, Azide and BSA Free and earn rewards!

Have you used CGRP1 Antibody - Humanized, IgG4SP, (Research Grade galcanezumab Biosimilar) - Low Endotoxin, Azide and BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies